Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb (BMY) reported Q3 revenues of $11.89 billion, surpassing expectations. Growth was driven by its Growth Portfolio and Eliquis. Analysts are cautious about the new schizophrenia treatment, KarXT (Cobenfy), with significant revenue expected post-2025. BMY stock is down 1.91%.
November 01, 2024 | 6:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bristol Myers Squibb reported Q3 revenues of $11.89 billion, exceeding expectations. Growth was driven by its Growth Portfolio and Eliquis. Analysts are cautious about the new schizophrenia treatment, KarXT (Cobenfy), with significant revenue expected post-2025. BMY stock is down 1.91%.
Bristol Myers Squibb's Q3 earnings exceeded expectations, driven by strong performance in its Growth Portfolio and Eliquis. However, analysts remain cautious about the new schizophrenia treatment, KarXT, with significant revenue not expected until after 2025. The stock is currently down 1.91%, reflecting mixed investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100